Skip to Main Content
  • McGraw Hill Medical
  • McGraw Hill Medical
    • Umbrella Logo Dropdown McGraw Hill Medical Home
    • Explorar m?s sitios
      AccessAnesthesiology
      AccessAPN
      AccessBiomedical Science
      AccessCardiology
      AccessDermatologyDxRx
      AccessEmergency Medicine
      AccessHemOnc
      AccessMedicina
      AccessMedicine
      AccessNeurology
      AccessObGyn
      AccessPediatrics
      AccessPharmacy
      AccessPhysiotherapy
      AccessSurgery
      Case Files Collection
      Clinical Sports Medicine Collection
      F.A. Davis AT Collection
      F.A. Davis PT Collection
      JAMAevidence
      Murtagh Collection
      OMMBID
      Pharmacotherapy Principles & Practice
  • Soporte técnico
    • Recursos para usuarios
    • ¿Quiénes somos?
    • Contáctenos
    • Enviar retroalimentación
  • Suscripciones
Iniciar sesión Sign In

Inicio de sesión MyAccess

Crear un perfil gratuito MyAccess
¿Olvidó su contraseña?
¿Olvidó su nombre de usuario?

Acerca de MyAccess

Si su institución se suscribe a este recurso y usted no tiene un perfil MyAccess, por favor póngase en contacto con el departamento de referencia de su biblioteca para obtener información sobre cómo acceder a este recurso desde fuera del campus.

Leer más
Inicie sesión mediante OpenAthens
Inicie sesión mediante Shibboleth
AccessMedicina home page Home
Navigation Menu Search Menu
  • Libros
  • Referencia rápida
    • Diagnosaurus®
    • Pruebas de diagnóstico
    • Guías
    • Calculadoras
    • 2 Minute Medicine®
    • Acrónimos
  • Fármacos
    • Monografías de fármacos
    • Interacción de fármacos
  • Multimedia
    • Animaciones 3D
    • Anatomía 3D - Módulos
    • Anatomía 3D - Desafío de anatomía
    • COVID-19
    • Harrison Podclass
    • Vídeos por aparatos y sistemas
    • Lecciones de farmacología
    • Harrison Animaciones de fisiopatología
    • Medicina de urgencias
  • Infografías
  • Casos
    • Casos
    • Desequilibrios hidroelectrolíticos/trastornos
    • Fisiopatología
    • Harrison Casos. Desafío visual
  • Autoevaluación
    • Por Recurso
    • Flashcards
  • Educación del paciente
     
    Acerca de búsqueda
    Enable Autosuggest
    ¡Bienvenido!

    Ha creado correctamente un Perfil de MyAccess para
    alertsuccessName.

    Las características de MyAccess incluyen:
    • Acceso remoto
    • Favoritos
    • Guardar figuras en PowerPoint
    • Descargar cuadros como archivos PDF
    Ir al Panel de control  Cerrar
    Inicio > 2 Minute Medicine® > Dermatology >
    Book cover
    Editors and Contributors

    Improved progression-free survival in patients with advanced melanoma treated with relatlimab and nivolumab

    by Kassandra McFarlane, Samuel Chan
    +

    Originally published by 2 Minute Medicine® (view original article). Reused on AccessMedicine with permission.

    +

    1. Median progression-free survival is higher with combination treatment of relatlimab and nivolumab

    +

    2. Adverse events were more frequent in the combination treatment group

    +

    Evidence Rating Level: 1 (Excellent)

    Study Rundown:

    +
    +

    The activity and safety of relatlimab (LAG-3 inhibitor) and nivolumab (PD1 inhibitor) has not previously been assessed in patients with untreated advanced melanoma. This study explored the effect of this combination of immune checkpoint inhibitors on progression-free survival (PFS), safety, and overall survival in patients with advanced melanoma. The primary outcome was progression-free survival, while secondary outcomes included safety and overall survival (OS). 714 patients twelve years and older were randomly allocated in a 1:1 ratio to receive nivolumab with or without relatlimab (n = 355 and 359, respectively). Median PFS was longer at 10.1 months in the combination treatment group as compared to the nivolumab-only group at 4.6 months. Adverse events were more common in the combination treatment group as compared to the nivolumab-only group, and OS results have not matured. There were no significant differences between the groups for health-related quality of life measures. Limitations to this study include the absence of results for all outcomes (i.e., overall survival) as well as limited power to make concrete conclusions. Overall, this trial demonstrates that dual inhibition of LAG-3 and PD-1 is another therapeutic option for advanced melanoma.

    +

    Click to read the study in The New England Journal of Medicine

    +

    Click to read an accompanying editorial in The New England Journal of Medicine

    +

    Relevant Reading: CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma

    In-Depth [randomized controlled trial]:

    +
    +

    This phase 3 trial conducted at 111 sites around the world randomly allocated 714 patients aged 12 and older with advanced melanoma (either untreated metastatic or inoperable) to receive either nivolumab only (n = 359) or nivolumab and relatlimab (n = 355). The primary outcome was progression-free survival and it was found that the combination-treatment group had a median PFS of 10.1 months (95% confidence interval (CI), 6.4-15.7 months), whereas the nivolumab-only treatment group had a median PFS of 4.6 months (CI, 3.4 to 5.6 months) (hazard ratio (HR), 0.75; 95% CI, 0.62-0.92). At one year, PFS was 47.7% in the combination treatment group (95% CI, 41.8 to 53.2%) and 36.0% in the nivolumab-only group (95% CI, 30.5 to 41.6%). Safety and OS were secondary outcomes. The combination treatment group had a greater number of grade 3 or 4 adverse events (AEs) than the single treatment group (18.9% compared to 9.7%), but no new safety signals were seen in the combination treatment group. 14.6% of patients in the combination treatment group discontinued treatment due to AEs as compared to 6.7% of the nivolumab-only group. 0.8% of deaths in the combination treatment and 0.6% of deaths in the nivolumab-only group were considered treatment-related. OS has not matured at this time and will remain blinded.

    +

    ©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

    Pop-up div Successfully Displayed

    This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

    Please Wait

    2MM Topics
    Chronic Disease
    Dermatology
    Oncology

    AccessMedicina

    • Libros
    • Referencia rápida
    • Diagnosaurus®
    • Pruebas de diagnóstico
    • Guías
    • Calculadoras
    • 2 Minute Medicine®
    • Acrónimos
    • Fármacos
    • Monografías de fármacos
    • Interacción de fármacos
    • Multimedia
    • Animaciones 3D
    • Anatomía 3D - Módulos
    • Anatomía 3D - Desafío de anatomía
    • COVID-19
    • Harrison Podclass
    • Vídeos por aparatos y sistemas
    • Lecciones de farmacología
    • Harrison Animaciones de fisiopatología
    • Medicina de urgencias
    • Infografías
    • Casos
    • Casos
    • Desequilibrios hidroelectrolíticos/trastornos
    • Fisiopatología
    • Harrison Casos. Desafío visual
    • Autoevaluación
    • Por Recurso
    • Flashcards
    • Educación del paciente
    • Acerca de

    McGraw Hill Medical

    • Sites
    • AccessAnesthesiology
    • AccessAPN
    • AccessBiomedical Science
    • AccessCardiology
    • AccessDermatologyDxRx
    • AccessEmergency Medicine
    • AccessHemOnc
    • AccessMedicina
    • AccessMedicine
    • AccessNeurology
    • AccessObGyn
    • AccessPediatrics
    • AccessPharmacy
    • AccessPhysiotherapy
    • AccessSurgery
    • Case Files Collection
    • Clinical Sports Medicine Collection
    • F.A. Davis AT Collection
    • F.A. Davis PT Collection
    • JAMAevidence
    • Murtagh Collection
    • OMMBID
    • Pharmacotherapy Principles & Practice
    • Soporte técnico
    • Recursos para usarios
    • ¿Quiénes somos?
    • Contáctenos
    • Enviar retroalimentación
    • Suscripciones
    • Suscripciones Institucionales
    • Suscripciones individuales
    McGraw Hill

    Copyright © McGraw Hill
    Todos los derechos reservados.
    Su dirección IP es 3.222.251.91
    Términos de uso   •  Aviso de privacidad   •  Anuncio   •  Soporte de Navegador

    Silverchair
    Arriba
    >
    Este sitio usa cookies. Al continuar navegando en este sitio, usted acepta nuestro uso de cookies. Más información Cerrar